Cortado Ventures, an investment firm announced a strategic investment in CorriXR Therapeutics, a cance-focused biotherapeutics development company with gene editing platform technology.
The dollar amount of the investment from the Oklahoma City company was not disclosed.
This investment solidifies Cortado’s commitment to advancing cutting-edge medical solutions and supporting the development of groundbreaking treatments for cancer, a release stated.
CorriXR Therapeutics, the first biotech spin-out of ChristianaCare and the Gene Editing Institute, the only gene editing institute in the U.S. at a non-academic community-based hospital system, has developed a gene editing platform utilizing a unique CRISPR/Cas biomolecular tool. The company’s initial focus is on treating squamous cell carcinoma of the lung, esophagus, and head and neck. The technology holds promise for a wide range of solid tumors, including glioma, pancreas, ovarian, bladder, melanoma, and thyroid cancers.
“We are excited to announce our investment in CorriXR Therapeutics, a company at the forefront of biotherapeutics development,” said Nathaniel Harding, managing partner at Cortado Ventures. “Their groundbreaking gene editing platform has the potential to revolutionize cancer treatment, offering hope to patients facing various solid tumors. Cortado is proud to support CorriXR’s mission to advance innovative and effective therapies. In addition, we are proud to support our Entrepreneur-in-Residence, Deborah Moorad, as she transitions into the role of CEO of CorriXR.”
CorriXR Therapeutics achieved a significant milestone by receiving positive feedback from the FDA during an INTERACT meeting, prompting consideration for a trial encompassing lung, esophageal, and head and neck squamous cell carcinoma. CorriXR Therapeutics plans on a Pre-Investigational New Drug application (pre-IND) meeting this year, anticipating clinical trials starting the first quarter of 2025.
“The investment from Cortado will help us expand our oncology pipeline and prepare for our clinical launch,” Moorad said. “Our upcoming milestones include additional data for more tumor targets, and initiation of our first clinical trial. The Cortado investment is very instrumental in our development plan and reaching a critical inflection point — first in human clinical data.”
See earlier story below
